0000000000351935

AUTHOR

Carole Monterymard

showing 5 related works from this author

The TDS-bands plot: a new graphical tool for Temporal Dominance of Sensations data

2010

[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal …

2018

Brachial Plexus Neuritismedicine.medical_specialtybusiness.industryPhases of clinical researchHematologyGastroenterology03 medical and health sciencesLarge Intestine Adenocarcinomachemistry.chemical_compound0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicineRegorafenibmedicine030211 gastroenterology & hepatologyColorectal adenocarcinomaIn patientPreviously treatedbusinessAnnals of Oncology
researchProduct

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unk…

2021

Abstract Background Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion crit…

OncologyMaleFOLFIRINOXmedicine.medical_treatmentLeucovorinPhases of clinical researchPlatinum Compounds0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesNeoplasm MetastasisEtoposideEtoposideGastroenterologyEvaluable DiseaseProgression-Free Survival3. Good healthFOLFIRINOXOxaliplatinSurvival RateNeuroendocrine TumorsTreatment Outcome030220 oncology & carcinogenesisNeuroendocrine carcinoma030211 gastroenterology & hepatologyFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyIrinotecanGastroenteropancreatic03 medical and health sciencesStomach NeoplasmsInternal medicineIntestinal NeoplasmsmedicineChemotherapyHumansContraindicationChemotherapyHepatologyPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCarcinoma NeuroendocrinePancreatic NeoplasmsRegimenQuality of LifeNeoplasms Unknown PrimarybusinessBiomarkersDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colore…

2020

International audience; BACKGROUND: Regorafenib significantly increases overall survival (OS) in patients with metastatic colorectal cancer previously treated but gives toxicities. OBJECTIVES: to assess the efficacy and safety of regorafenib at it's approved dose in the older population. PATIENTS AND METHODS: This multicenter single-arm phase II enrolled patients ≥70 years old after the failure of fluoropyrimidine-based chemotherapy, anti-VEGF, and anti-EGFR treatment. The primary endpoint was disease control rate (DCR) 2 months after initiation of regorafenib (160 mg/day, 3 weeks on/1 week off). RESULTS: Forty-three patients were enrolled, with a median age of 77 years. The 2 months DCR wa…

medicine.medical_specialtyColorectal cancerPyridinesmedicine.medical_treatment[SDV]Life Sciences [q-bio]AdenocarcinomaGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineQuality of lifeRegorafenibInternal medicinemedicineClinical endpointHumans030212 general & internal medicineAdverse effectChemotherapybusiness.industryPhenylurea Compoundsmedicine.disease3. Good health[SDV] Life Sciences [q-bio]DiarrheaOncologychemistry030220 oncology & carcinogenesisToxicityQuality of LifeGeriatrics and Gerontologymedicine.symptombusinessColorectal Neoplasms
researchProduct

TimeSens, a Web-based sensory software for Temporal Dominance of Sensations

2011

TimeSens, a Web-based sensory software for Temporal Dominance of Sensations. 9. Pangborn sensory science symposium

[SDV.AEN] Life Sciences [q-bio]/Food and Nutritiondominance temporelle des sensationssoftwareComputerApplications_MISCELLANEOUS[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionlogicielapplication web[SDV.AEN]Life Sciences [q-bio]/Food and NutritionGeneralLiterature_MISCELLANEOUS
researchProduct